Tremelimumab plus Durvalumab in First- or Second-Line Mesothelioma Patients: Final Analysis of the NIBIT-MESO-1 Study
JOURNAL OF THORACIC ONCOLOGY(2017)
关键词
Immunotherapy,Mesothelioma,Immune checkpoint blockade
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要